Company Overview and News

 
China shares on track for 9th straight session gains

2018-01-10 thehindubusinessline
China shares rose early Wednesday, led by banking and consumer stocks, and were on track to climb for a ninth straight session.

 
AirAsia could sell leasing arm after strategic review

2016-08-26 reuters
KUALA LUMPUR Asia's biggest budget airline AirAsia Bhd (AIRA.KL) is considering options for its leasing arm, including a potential sale, the company said on Friday.

 
CITIC Bank president says CTBC deal cancellation due to commercial reasons

2016-08-26 reuters
BEIJING The cancellation of investment deals between China CITIC Bank Corp Ltd (601998.SS) (0998.HK) and Taiwan's CTBC Financial Holdings (2891.TW) was mainly due to financial regulation and commercial reasons and had nothing to do with politics, the president of the mainland bank said on Friday.

 
CITIC Bank president says CTBC deal cancellation due to commercial reasons

2016-08-26 channelnewsasia
BEIJING: The cancellation of investment deals between China CITIC Bank Corp Ltd and Taiwan's CTBC Financial Holdings was mainly due to financial regulation and commercial reasons and had nothing to do with politics, the president of the mainland bank said on Friday.

 
China's CITIC Bank And Uber To Issue Co-Branded Credit Cards | News Moving Markets

2016-06-30 newsmovingmarkets
Photo taken on April 14, 2016 shows a Uber car-hailing station in Longyang Avenue, Wuhan, capital of central China's Hubei province.[Photo/IC] China CITIC Bank Corp Ltd and Uber Technologies Inc announced the launch of a co-branded credit card on Wednesday, taking the first step toward a strategic partnership globally. Emil Michael, chief business officer of Uber,…

 
UPDATE 1-China's CITIC Bank tries to seize real estate assets in Canada

2016-06-28 reuters
VANCOUVER, June 27 China CITIC Bank Corp Ltd has launched a Canadian lawsuit to try to seize the assets of a Chinese citizen the bank claims took out a multi-million dollar loan in China then fled to Canada, the lender's Vancouver-based lawyer said on Monday.

 
China’s CITIC Bank tries to seize real estate assets in Canada

2016-06-28 financialexpress
China CITIC Bank Corp Ltd  has launched a Canadian lawsuit to try to seize the assets of a Chinese citizen the bank claims took out a multi-million dollar loan in China then fled to Canada, the lender’s Vancouver-based lawyer said on Monday.

 
China's CITIC Bank tries to seize real estate assets in Canada

2016-06-28 reuters
VANCOUVER, June 27 China CITIC Bank Corp Ltd has launched a Canadian lawsuit to try to seize the assets of a Chinese citizen the bank claims took out a multi-million dollar loan in China then fled to Canada, the lender's Vancouver-based lawyer said on Monday.

 
UPDATE 1-ChemChina to fund $43 bln Syngenta bid with recourse, non-recourse debt-LPC

2016-02-04 reuters
* ChemChina aims to keep Syngenta's investment grade rating (Adds deal advisors, expected fees, breakdown of debt)

 
ChemChina to fund $43 bln Syngenta bid with recourse, non-recourse debt-LPC

2016-02-04 reuters
HONG KONG Feb 4 State-owned China National Chemical Corp (ChemChina) plans for a mix of recourse and non-recourse loans to fund a $43 billion bid for Swiss seeds and pesticides group Syngenta, Thomson Reuters LPC said on Thursday, citing banking sources familiar with the plans.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...